Skip to main content
INMB logo

INMB · Inmune Bio, Inc.

Track INMB — free
$0.88 -0.01 (-1.58%)
Market Cap
$27.68M
Shares
30.96M
Volume · Nov 19 418.86K Avg daily vol (3M) 342.92K

Price & Indicators

 

Key stats

Close
$0.89
Open
$1.03
Day range
$0.89–1.03
52-week closing range
$0.89–2.51
Average volume, 30 days
350K
Short interest
2.7M · 8.6% of shares · 14.4 days
Short volume, last session
70%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

Dec 30, 2026 Est · unconfirmed · in 6 wks

Latest documents

2026
Nov 5
Earnings call
Ebstracell UK application targets early February 2027

ImmuneBio targets an early February 2027 UK application for Ebstracell, with potential approval by the middle of the year, and says cash will fund operations through Q3 2027.

3 source passages
We remain on track to complete a U.K. marketing authorization application in early February 2027, with potential U.K. approval by the middle of the year. We thank you for joining the call for ImmuneBio's third quarter 2026 financial results. Also, during October, the company raised $4.5 million in gross proceeds from the sale of common stock and warrants to an investor, and based on our current operating plan, we believe our cash is sufficient to fund our operations through Q3 of 2027. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
CORDStrom targets 2027 filings as going concern persists

INmune Bio plans to file CORDStrom’s UK Marketing Authorization Application during February 2027 and an FDA Biologics License Application at mid-2027. It reported a $11.4 million nine-month net loss, $16.3 million cash, and substantial doubt about continuing as a going concern.

Net loss $4.72M Diluted EPS -$0.17
Read from the MD&A section
6 source passages
CORDStrom has recently completed a pivotal, blinded, randomized cross-over trial. We intend to file a Marketing Authorization Application (“MAA”) in the United Kingdom during February 2027, followed by a Biologics License Application (“BLA”) with the U.S. Food and Drug Administration (“FDA”) planned for mid-2027 and then the European Union application. INmune Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to reprogram the innate immune system. We reported a net loss of $11.4 million for the nine months ended September 30, 2026. As of September 30, 2026 and December 31, 2025, we had cash and cash equivalents of $16.3 million and $24.8 million, respectively. Our recurring net losses and negative cash flows from operations raised substantial doubt regarding our ability to continue as a going concern within one year after the issuance of our unaudited condensed consolidated financial statements for the nine months ended September 30, 2026. Open the document at this passage
Oct 29
Current report 8-K Events of Oct 27
Direct offering raises $4.5 million with warrants

Inmune Bio agreed to sell 3,000,000 shares at $1.50 per share and issue unregistered warrants for up to 3,000,000 additional shares, generating expected aggregate gross proceeds of $4.5 million before fees and expenses.

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure Read from the first part of this long document
3 source passages
On October 27, 2026, INmune Bio Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser, in a registered direct offering (the “Registered Direct Offering”), 3,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $1.50 per share. In a concurrent private placement (the “Private Placement” and, together with the Registered Direct Offering, the “Offering”), the Company also agreed to issue to the Purchaser unregistered warrants (the “Common Warrants”) to purchase up to 3,000,000 shares of Common Stock (the “Common Warrant Shares”). The Company expects to receive aggregate gross proceeds of $4.5 million from the Offering, before deducting placement agent fees and offering expenses and excluding the proceeds, if any, from the exercise of the Common Warrants sold in the Private Placement. Open the document at this passage
Oct 21
Current report 8-K
Ebstrocel pre-MAA package submitted to UK MHRA; Uniphar agreement signed

INmune Bio submitted its final pre-Marketing Authorisation Application package to the UK MHRA for Ebstrocel on October 20, 2026. The company targets a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review. It also entered into a Master Services Agreement with Uniphar Durbin Ireland Limited and expects to submit a U.S. BLA in Q2 2027.

Regulation FD disclosure, Other events
5 source passages
Final pre-MAA package submitted to MHRA on October 20, 2026 Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks with potential UK approval in mid-2027, subject to MHRA review entered into a Master Services Agreement with Uniphar Durbin Ireland Limited U.S. BLA expected to be submitted in Q2, 2027 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$50,000
Trailing 12 months
Net income (TTM)
−$16.67M
Trailing 12 months
Revenue growth YoY
+257.1%
Year over year
Operating margin
-94,766.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.6%
Year over year · more shares
Price change (1Y)
-40.8%
Trailing year
Short interest
8.6%
Latest settlement · 14.4 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −44%
below
Price vs 50-day avg −46%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −42%
trailing
6-month return −36%
trailing
YTD return −43%
this year
Relative strength −30%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-23% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.59% of shares out · ▼ -7.9% MoM · 14.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
63 holders — mid 3-yr range
Squeeze score 58
elevated · 0–100
Fundamentals
Strong
Revenue growth +257%
Y/Y
EPS growth +12%
Y/Y
Free cash flow $-23.6M
Balance sheet $5.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 76%
annualized · 1-yr
Max drawdown −64%
past year
ATR 13.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−44% Bearish
Price vs 50-day avg
−46% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-23% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.59% of shares out · ▼ -7.9% MoM · 14.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
63 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $3
vs 200-day avg -44% vs 50-day avg -46%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INMB
Inmune Bio, Inc.
this stock
$27.68M -42.7% +257.1% — 8.6%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
63
% held
14.5%
Net QoQ
+137.2K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
13
View
Short & Settlement
Short Interest Falling
Shares short
2.7M
Days to cover
14.4d
Change
-227.8K sh
View
Short Volume
Short vol %
70%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
474
Value
$730
As of
Oct 23, 2026
View
Off-Exchange
Off-exchange %
62.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$50.0K
Net income (FY)
$-45.9M
EPS diluted
$-1.86
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
20

INmune Bio plans to file CORDStrom’s UK Marketing Authorization Application during February 2027 and an FDA Biologics License Application at mid-2027. It reported a $11.4 million nine-month net loss, $16.3 million cash, and substantial doubt about continuing as a going concern.

View
Proposed Sales
Value
$960.1K
Shares
60.0K
Filed
Jul 12, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
INmune Bio Inc. Announces Third Q…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
INMB -14.9% -41.9% -35.7% -38.3% -42.7%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -9.4% -35.7% -30.1% -33.1% -47.7%
Key facts CIK 1711754 CUSIP 45782T105 13F (30d) 70 filings 58 filers Visit website Investor relations